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AbsTrACT
Introduction Liver cirrhosis is the fifth largest cause of 
adult deaths, and a major complication, variceal bleeding 
is associated with a 1-year mortality of 40%. There is 
uncertainty on the first-line therapy for prevention of 
variceal bleeding owing to a lack of adequately powered 
trials comparing non-selective beta blockers, in particular 
carvedilol, with variceal band ligation.
Methods and analysis CALIBRE is a multicentre, 
pragmatic, randomised controlled, open-label trial with 
an internal pilot. The two interventions are carvedilol 
12.5 mg od or variceal band ligation (VBL). Patients 
with liver cirrhosis and medium to large oesophageal 
varices that have never bled are eligible for inclusion. The 
primary outcome is any variceal bleeding within 1 year 
of randomisation. Secondary endpoints include time to 
variceal bleed, mortality, transplant-free survival, adverse 
events, complications of cirrhosis, health-related quality 
of life, use of healthcare resources, patient preference and 
use of alternative or crossover therapies. The sample size 
is 2630 patients over a 4-year recruitment period, across 
66 hospitals in the UK.
Ethics and dissemination The study has been approved 
by a National Health Service (NHS) Research Ethics 
Committee (REC) (reference number 18/NE/0296). The 
results of this trial will be submitted for publication in a 
peer reviewed journal. Participants will be informed via 
a link to a preview of the publication. A lay summary will 
also be provided via email or posted to participants prior to 
publication (ISRCTN reference number: 73887615).
InTroduCTIon
Existing research and current practice
Liver disease is the fifth largest cause of adult 
deaths,1 2 with mortality predicted to double 
in 20 years.1 Patients with liver disease die 
younger with the average age of death of 59 
years, compared with 82–84 years for heart 
and lung disease and stroke.1 One of the 
major complications of cirrhosis is portal 
hypertension and variceal bleeding. In 
patients with cirrhosis, varices develop at a 
rate of 5% per year with 10 year cumulative 
incidence of 44%.3 At least 3000 patients are 
admitted to hospital in England per year with 
variceal bleeding, with inpatient mortality 
of 15% and 1-year mortality of up to 40%. 
Increased hospitalisation results in increased 
use of secondary care and substantial health-
care costs. Since many patients are of working 
age there are also significant societal impli-
cations. Therefore, reducing the risk of the 
first variceal bleed (primary prevention) is an 
important clinical and economic goal.
At present, there are two options for 
primary prevention of variceal bleeding, 
namely non-selective beta-blockers and vari-
ceal band ligation. Beta-blockers used for 
portal hypertension in the UK are propran-
olol and carvedilol. A Cochrane review and 
meta-analysis of 19 trials (with a total of 1504 
patients) comparing variceal band ligation 
versus beta-blockers showed a reduced risk of 
variceal bleeding with variceal band ligation 
(risk ratio, 0.67; 95% CI 0.46 to 0.98) with 
no effect on survival.4 However, the overall 
quality of evidence was low to moderate. 
When only high quality trials (seven trials, 
713 patients) with minimal bias and suffi-
cient follow-up were studied, the difference 
in bleeding rates was no longer evident. In 
another meta-analysis, although adverse 
events were more frequent with beta-blockers 
(OR 2.61, 95% CI 1.60 to 4.40, p<0.0001), 
fatal adverse effects were significantly lower 
with non-selective beta-blockers (NSBB; OR 
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0.14, 95% CI 0.02 to 0.99, p<0.05).5 The fatalities relate 
to banding induced bleeding from ulcers. No adverse 
events from beta-blockers such as symptomatic hypo-
tension, dyspnoea and gastrointestinal upset directly 
resulted in death.
Trial rationale
The main focus of the research is the comparison of 
beta-blockers and variceal band ligation in the preven-
tion of the first variceal bleed. There have been two 
important guidelines published in the UK in 2015–2016 
from NICE and the British Society of Gastroenterology 
(BSG).3 6 NICE favours banding for primary preven-
tion, whereas the BSG suggests banding if the patient 
is intolerant of beta-blockers. The recommendations of 
the BSG guidelines are similar to those of international 
guidelines.7 8 Therefore, there is at present disparity in 
the current guidelines with regard to first-line therapy for 
primary prevention.
Many specialists have significant concerns about the 
adverse effects of variceal band ligation, in particular 
the risk of banding induced bleeding.4 5 There are also 
concerns about the use of beta-blockers in patients with 
advanced cirrhosis with some studies showing higher 
mortality9 10 while others report improved survival.11 In 
particular with carvedilol, improved survival has been 
suggested.12 None of these studies are randomised trials 
and are therefore limited by their designs and the poten-
tial for confounding and other biases.
Data on cost effectiveness in the context of primary 
prevention are available from just one publication.13 
This suggested beta-blockers have reduced overall costs 
compared with variceal band ligation. However, in the 
2016 National Institute for Health and Care Excellence 
(NICE) cirrhosis guidelines, after extrapolation of the 
meta-analysis showing less bleeding with variceal band 
ligation, variceal band ligation was found to be more cost 
effective.6 There are no cost effectiveness studies along-
side a randomised controlled trial (RCT) comparing 
carvedilol with variceal band ligation.
A large RCT at this time would help clinicians decide 
on the best treatment in terms of clinical and cost-effec-
tiveness, as the current evidence is based on underpow-
ered and low-quality trials as detailed above.
Carvedilol has been selected as the beta-blocker for 
this trial. Carvedilol is a well-tolerated non-selective beta-
blocker which reduces portal blood flow, and in addition 
has vasodilating actions due to alpha-1 receptor blockade. 
The latter helps to reduce portal pressure further, mainly 
through the effects on intrahepatic resistance. Haemo-
dynamic studies demonstrate a greater reduction in 
portal pressure than propranolol, and carvedilol can be 
effective even in patients not responding to propran-
olol.14 Carvedilol also has pleiotropic anti-inflammatory, 
antioxidant and antifibrotic properties along with other 
roles in enhancing insulin sensitivity and improving mito-
chondrial function that may provide additional bene-
fits in patients with cirrhosis.15 Propranolol is not always 
well tolerated, and a third of patients fail to achieve a 
satisfactory reduction in portal pressure. Nadolol is not 
commonly used in the UK and has similar haemodynamic 
efficacy as propranolol. Therefore, there is considerable 
interest in alternatives to propranolol/nadolol, such as 
carvedilol.
There are only two RCTs of carvedilol versus variceal 
band ligation in primary prevention.16 17 The first trial 
from the UK of 152 patients showed significantly reduced 
bleeding in the carvedilol arm (10% vs 23%, relative 
hazard 0.41; 95% CI 0.19 to 0.96), with no apparent 
effect on survival (35% vs 37%, relative hazard 0.91; 95% 
CI 0.53 to 1.55).17 The second trial from Pakistan of 168 
patients did not show any differences in bleeding (8.5% 
vs 6.9%, relative hazard 1.61; 95% CI 0.27 to 9.69) or 
mortality (12.8% vs 19.5%, relative hazard 1.53; 95% CI 
0.71 to 3.30).16 In the first trial, patients were randomised 
after endoscopy with delays in the first banding session, 
leading to a lead time bias against band ligation as a second 
endoscopy session was required. CALIBRE endeavours to 
minimise this bias by randomisation mainly at the time of 
endoscopy. Compliance with variceal band ligation was 
better in the second trial, but significantly more patients 
had viral hepatitis than alcohol-related cirrhosis which 
does not reflect the disease burden of the UK. A recent 
randomised placebo controlled trial of 140 patients 
showed that carvedilol reduced progression of varices 
over a minimum of 24 months follow-up in patients with 
small varices, with no difference in bleeding or survival.18 
Furthermore, the Mayo group recently performed a 
network meta-analysis which recommends further larger 
prospective trials of carvedilol in cirrhosis to investigate 
its potential benefits.19
The results of this trial will provide high-quality data 
with adequate power and follow-up. If carvedilol is found 
to be superior to variceal band ligation, then it will 
become first-line therapy in primary prevention. The trial 
will also provide a unique cohort for extended follow-up, 
since consent will be sought to use routine long-term 
data. This will help us understand the long-term impact 
of beta-blockers. It is plausible that survival may be better 
with carvedilol than variceal band ligation as suggested 
in a study of beta-blockers in secondary prevention.20 
If this is true, it will lead to a paradigm shift in primary 
prevention of variceal bleeding. Such a finding will also 
encourage further translational research into the under-
lying mechanisms, which could help stratify patients most 
likely to benefit from beta-blockers and offer alternative 
therapies to non-responders.
Beta-blockers as first-line therapy in primary preven-
tion will lead to a large change in practice as NICE 
guidance presently recommends variceal band ligation. 
Beta-blockers require much less National Health Service 
(NHS) resources than variceal band ligation for primary 
prevention, which usually requires at least 3–5 treatments 
to eradicate varices followed by indefinite endoscopic 
surveillance. There is no requirement for patients on 
carvedilol for primary prevention to undergo endoscopic 
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surveillance.3 Bed pressures for other elective procedures 
could be eased and waiting times improved.
Internal pilot trial
The first 12 months of the CALIBRE trial will constitute 
an internal pilot, to assess and confirm logistics, and to 
determine if it is both feasible and practical for the trial 
to continue. Integrated qualitative research with patients 
and staff will contribute to assessments of feasibility and 
acceptability as detailed later. The qualitative research 
could lead to changes in the trial protocol as necessary to 
minimise potential barriers to recruitment and facilitate 
recruitment in the main trial. The results of the internal 
pilot will be assessed by the Data Monitoring Committee 
(DMC), Trial Steering Committee (TSC) and the funder.
Primary objective
The primary aim of this study is to compare carvedilol 
versus variceal band ligation in preventing any variceal 
bleeding within 1 year of randomisation in patients with 
cirrhosis and medium to large oesophageal varices that 
have never bled.
secondary objectives
These include the effect of carvedilol and variceal band 
ligation on survival, development of other complications 
of cirrhosis and adverse events. The study will also inves-
tigate cost-effectiveness, patient preference and use of 
alternative or cross over therapies.
METhods And AnAlysIs
CAlIbrE trial design
CALIBRE is a multicentre, pragmatic, randomised 
controlled, open-label trial with an internal pilot. Approx-
imately 66 Acute NHS Trusts/Health Boards in the UK 
will be involved in trial recruitment. The detailed trial 
design is described below.
Eligibility criteria
To be eligible for CALIBRE, a patient must have cirrhosis, 
and medium varices (Grade II varices that do not flatten 
on air insufflation and do not occlude the lumen) or 
large varices (Grade III varices which are larger than 
Grade II varices and occupy the whole lumen) that have 
never bled as defined in the BSG guidelines.3 Detailed 
inclusion and exclusion criteria are illustrated in figure 1. 
Patients with portal vein thrombosis of any grade can be 
included in CALIBRE. Patient who are on propranolol, 
carvedilol or nadolol for primary prevention or those 
that have had band ligation will be excluded.
recruitment
Participants may be identified and recruited in one of the 
following ways (figures 2–4):
 ► By their Hepatologist, Gastroenterologist or Research 
Nurse in advance of standard of care variceal surveil-
lance endoscopy.
 ► Referral from an outpatient clinic following a diag-
nostic endoscopy.
 ► Identification from inpatient referrals.
Patient enrolment is expected to start in early 2019 and 
expected to end in 2022.
randomisation
Randomisation will be provided by a secure 24 hours 
online randomisation system at Birmingham Clinical 
Trials Unit (BCTU), supplemented by a telephone rando-
misation service.
After participant eligibility has been confirmed and 
informed consent has been received, the participant can 
be randomised into the trial. A randomisation form will 
be provided to investigators and will be used to collate 
the necessary information prior to randomisation. All 
questions and data items on the randomisation form 
must be answered before a trial number can be given. 
If data items are missing, randomisation will be stopped, 
restarting once the information is available. Only when 
all eligibility criteria and baseline data items have been 
provided will a trial number be allocated.
Participants will be randomised at the level of the indi-
vidual in a 1:1 ratio to either treatment with 12.5 mg 
carvedilol once daily or variceal band ligation. Both of 
these treatments will start on the same day as randomi-
sation or as soon as possible after. Patients randomised 
in clinic after a previous diagnostic endoscopy will be 
started on carvedilol 12.5 mg od or variceal band liga-
tion within 2 weeks of randomisation. A minimisation 
algorithm will be used within the online randomisation 
system to ensure balance in the treatment allocation over 
the following variables: presence or absence of hepatic 
decompensation (ascites or encephalopathy), size of 
the largest varix (Grade II or Grade III), age of patient 
at randomisation (18–50, 51–70, >70) and presence or 
absence of alcohol-related liver disease.
A ‘random element’ will be included in the minimi-
sation algorithm, so that each patient has a probability 
(unspecified here), of being randomised to the opposite 
treatment that they would have otherwise received. Full 
details of the randomisation specification will be stored 
in a confidential document at BCTU.
Trial treatment/intervention
Carvedilol
Participants will be prescribed 12.5 mg od. They will 
be seen in a follow-up clinic at 4 weeks to assess for any 
short-term adverse events such as symptomatic hypoten-
sion, gastrointestinal side effects like nausea, swelling of 
hands and feet, blurred vision, lethargy, headache, sexual 
dysfunction and shortness of breath.3 These patients will 
not be offered routine endoscopic surveillance, as per 
standard of care.3 Participants will be asked about adher-
ence with their trial medication at each follow-up visit 
and their response documented in the medical notes 
and subsequently transcribed onto the Follow-Up Case 
Report Forms (CRFs).
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Figure 1 Trial schema.
Variceal band ligation
The procedure will be performed as per the BSG guide-
lines.3 Adherence to variceal band ligation will be docu-
mented on the Follow-Up CRFs using information 
available in the participant’s medical notes.
Treatment modification
Figure 5 outlines the process for treatment modifica-
tions in the event of intolerance. At clinician’s discretion, 
participants that are intolerant of carvedilol or variceal 
band ligation can be crossed over to the other arm at any 
point.
outcome measures and study procedures
Primary outcome
Any variceal bleeding within 1 year of randomisation. 
The first variceal bleed is defined as hematemesis and/or 
melena with either: (1) endoscopic evidence of variceal 
bleeding or stigmata of recent haemorrhage and at least 
a 2 g/L reduction in haemoglobin within 24 hours of 
admission or (2) massive upper gastrointestinal bleeding 
leading to death. The definition includes bleeding from 
banding ulceration.3
Secondary outcomes
1. Time to first variceal bleed in days (from 
randomisation).
2. Mortality at 1 year (from randomisation):
1. All-cause mortality.
2. Liver related mortality.
3. Cardiovascular mortality.
3. Transplant free survival at 1 year (from 
randomisation).
4. Adverse events related to treatment (up to 12 months 
after randomisation):
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Figure 2 Consent process (planned endoscopy where no diagnosis of varices has yet been made).
1. Dysphagia requiring discontinuation of treatment.
2. Symptomatic hypotension requiring change in 
treatment.
3. Dyspnoea.
4. Gastrointestinal upset.
5. Other complications of cirrhosis:
1. New onset ascites confirmed clinically or on imag-
ing and graded as per International Club of Ascites 
recommendations.21
2. New onset encephalopathy defined using West 
Haven Criteria.22
3. Spontaneous bacterial peritonitis.
4. Hepatocellular carcinoma.
5. Any renal dysfunction as per International Club 
of Ascites—Acute Kidney Injury (ICA-AKI) 
definitions.23
6. Health-related quality of life (EQ-5D-5L) from ran-
domisation to 6 and 12 months.
copyright.
 o
n
 24 July 2019 by guest. Protected by
http://bmjopengastro.bmj.com/
BM
J O
pen G
astroenterol: first published as 10.1136/bmjgast-2019-000290 on 25 April 2019. Downloaded from 
6 Tripathi D, et al. BMJ Open Gastro 2019;6:e000290. doi:10.1136/bmjgast-2019-000290
Open access 
Figure 3 Consent process following referral from an outpatient clinic following diagnostic endoscopy.
7. Use of healthcare resources, costs and cost-effec-
tiveness based on the outcomes of cost per variceal 
bleeding avoided within 1 year of randomisation, 
cost per Quality-adjusted Life-year (QALY) estimated 
using the EQ-5D-5L and cost per death avoided at 1 
year.
8. Patient preference. We will conduct qualitative inter-
views with patients and staff during the pilot phase. 
These interviews will explore patients’ experience of 
and preferences related to treatment (Carvedilol or 
VBL). This will provide the basis to describe qualita-
tively patients’ experience of the trial interventions. 
These qualitative data will complement quantitative 
outcome assessment.
9. Use of alternative therapies.
10. Crossover therapies.
schedule of assessments
This is detailed in table 1.
statistical considerations
Sample size
The sample size calculation has been based on published 
data from both a Cochrane review and meta-analysis of 
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Figure 4 Consent process following an inpatient referral.
variceal banding versus beta-blockers4 and data from the 
first UK RCT of carvedilol published in this disease area.17 
The Cochrane meta-analysis reported an overall 1-year 
variceal bleeding rate of 12% in the variceal banding 
ligation group. The 1-year bleeding rate was chosen for 
the primary outcome as Kaplan-Meier curves suggest that 
the majority of variceal bleeding occurs in the first year 
after treatment.17 To detect a 33% proportional differ-
ence in variceal bleeding rates (ie, from 12% to 8%, a 4% 
absolute difference) between groups using a 2-sided test 
for comparison of proportions with a 1:1 allocation ratio, 
90% power and a type I error rate of 5% (ie, α=0.05), 
requires 2362 participants (1181 per group). Assuming 
and adjusting for a 10% attrition/loss to follow-up rate 
(based on the similar patient population,17 which is thus 
a conservative estimate due to our shorter duration of 
follow-up), increases the required sample size to 2630 
participants in total (1315 per group).
Analysis of outcome measures
A separate Statistical Analysis Plan (SAP) will be produced 
and will provide a more comprehensive description of 
the planned statistical analyses. A brief outline of these 
analyses is given below.
The primary comparison groups will be composed of 
those randomised to carvedilol versus those randomised 
to variceal band ligation. All analyses will be based on the 
intention-to-treat principle, that is, all participants will 
be analysed in the group to which they were allocated 
irrespective of compliance with the randomised allocated 
treatment or other protocol violations. For all major 
outcomes, summary statistics and differences between 
groups (eg, mean differences, relative risks) will be 
presented, with 95% CIs and p values from 2-sided tests 
also given. Treatment effects will be adjusted for the mini-
misation variables. P<0.05 will be considered statistically 
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Figure 5 Process for treatment modifications in the event of intolerance.
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Table 1 Schedule of assessments
Randomisation and 
baseline
4 weeks*±1 week
FU visit
6 months±2 months 
FU visit
12 months±2 
months FU visit
Confirm eligibility ✓
Seek informed consent ✓
Randomisation ✓
Medical history† ✓
Medication review ✓ ✓ ✓ ✓
Physical examination ✓‡§ ✓‡§ ✓‡§
Office blood pressure ✓ ✓ ✓ ✓
Pulse ✓ ✓ ✓ ✓
Standard care blood tests ✓‡ ✓‡ ✓‡
Height ✓‡
Weight ✓‡ ✓‡ ✓‡ ✓‡
Administer EQ 5D-5L ✓ ✓ ✓
Resource use (Follow-Up 
CRFs)
✓ ✓
Dispense trial medication*¶ ✓
Adverse event review and 
evaluation
✓ ✓ ✓
Adherence ✓ ✓
Qualitative interviews** ✓†† ✓
*Carvedilol arm only.
†Including aetiology of liver disease and past medical history (diabetes, ischaemic heart disease, pulmonary disease). AUDIC-C score will 
also be calculated where appropriate.
‡Taken from clinical records.
§Liver stiffness measurement using Fibroscan where available and appropriate.
¶Medication may initially be dispensed by site but can subsequently be dispensed by the participant’s community pharmacy.
**Pilot phase only.
††Follow-up qualitative interviews will be between 6 and 12 months.
CRF, Case Report Form.
significant and there will be no adjustment for multiple 
testing.
Primary outcome measures
The primary outcome measure of the study is variceal 
bleeding within the first year after randomisation. This 
outcome is a binary outcome (ie, yes/no). The number 
and percentage of participants experiencing variceal 
bleeding within 1 year of randomisation will be reported 
by treatment group. An adjusted relative risk and 95% CI 
will be estimated from a log-binomial model to take into 
account the minimisation variables.
The p value from the associated χ² test will be produced 
and used to determine statistical significance.
secondary outcome measures
The secondary outcomes for the trial include contin-
uous, categorical and time-to-event data items.
Time-to-event outcomes (eg, time to first variceal bleed)
Time to event outcomes will be compared between treat-
ment groups using standard survival analysis methods. 
Kaplan-Meier survival curves will be constructed for 
visual presentation of time-to-event comparisons. Cox 
proportional hazard models will be fitted to obtain 
adjusted treatment effects which will be expressed as HRs 
with 95% CIs.
Categorical outcomes (eg, dysphagia requiring discontinuation of 
treatment)
For binary secondary outcomes, the number and 
percentage of participants reporting each outcome will 
be reported by treatment group. An adjusted relative risk 
and 95% CI will be estimated from a log-binomial regres-
sion model. The p value from the associated χ² test will be 
produced and used to determine statistical significance.
Continuous outcomes (EQ-5D-5L)
Continuous outcomes will be reported using means and 
SD. The EQ-5D-5L will be compared between treatment 
groups with adjusted mean differences and 95% CIs 
estimated using linear regression models. Change in 
EQ-5D-5L score from baseline will also be modelled.
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Economic evaluation
A separate Health Economics Analysis Plan will be 
produced, providing a comprehensive description of the 
planned economic evaluation. Briefly, a within-trial anal-
ysis will be conducted from a National Health Service and 
Personal Social Services (NHS/PSS) perspective to calcu-
late cost per variceal bleed avoided, cost per QALY gained 
and cost per death avoided. If evidence from the trial shows 
differences in terms of important outcomes (eg, rebleeding 
or mortality) that have significant cost or outcome impli-
cations beyond the trial period, a model-based economic 
evaluation will additionally be conducted.
Analysis of qualitative data
During the internal pilot, interviews will be recorded 
with the consent of participants and transcribed clean 
verbatim for analysis. Analysis will be conducted with 
reference to recordings, transcripts and field notes 
taken at the time of data collection. A thematic analysis 
of content will be informed by the Framework analytical 
approach.24 Following initial familiarisation with the 
interview data, development of thematic frameworks 
and data coding will proceed in an iterative manner. 
Data collection and analysis will run concurrently so 
that emergent analytical themes can inform further 
data collection, and particularly comparative analytical 
questioning between patients allocated to carvedilol 
and variceal band ligation.
Planned subgroup analyses
Subgroup analyses will be limited to the same variables used 
in the minimisation algorithm. Subgroup analyses will be 
limited to the primary outcome. Tests for statistical hetero-
geneity will be performed prior to any examination of 
effect estimates within subgroups. The results of subgroup 
analyses will be treated with caution and will be used for the 
purposes of hypothesis generation only.
Missing data and sensitivity analyses
Every attempt will be made to collect full follow-up data 
on all study participants, and it is thus anticipated that 
missing data will be minimal. Participants with missing 
primary outcome data will not be included in the primary 
analysis in the first instance. This presents a risk of bias, 
and sensitivity analyses will be undertaken to assess the 
possible impact of the risk. In brief, this will include worst-
case assumptions and/or multiple imputation methods. 
Further sensitivity analyses will include an analysis on the 
per-protocol population and an unadjusted analysis. Any 
sensitivity analyses will not, irrespective of their differences, 
supplant the planned primary analyses. Full details will be 
included in the SAP.
Planned interim analyses
Interim analyses of major outcome measures and safety 
data will be conducted and provided in strict confidence 
to the independent DMC. Details of the agreed plan will be 
written in the SAP.
Planned final analyses
The final analysis for the study will occur once all partic-
ipants have completed the 1-year assessment, and the 
corresponding outcome data have been validated as 
ready for analysis.
EThICs And dIssEMInATIon
Ethical considerations
CALIBRE was granted ethical approval by the North 
East—York Research Ethics Committee (REC), refer-
ence number: 18/NE/0296. The trial will be conducted 
in accordance with the UK Policy Framework for Health 
and Social Care Research 2017, the applicable UK Statu-
tory Instruments (which include the Medicines for Human 
Use Clinical Trials 2004 and subsequent amendments and 
current UK Data Protection Regulations). This trial will be 
carried out under a Clinical Trial Authorisation (CTA) in 
accordance with the Medicines for Human Use Clinical 
Trials regulations.
dissemination
Results of this trial will be submitted for publication in a 
peer reviewed journal. The manuscript will be prepared by 
the CI or delegate and authorship will be determined by 
the trial publication policy. Participants will be informed 
of the outcome of the trial via a link to a preview of the 
publication. A lay summary will also be provided via email 
or posted to participants prior to publication.
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